Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France
Table 2
Patient characteristics, overall and by country.
Characteristic
Overall ()
UK ()
Spain ()
Germany ()
France ()
n
%
n
%
n
%
n
%
n
%
Sex
Male
475
58.9
126
63.3
123
60.6
130
63.7
96
47.8
Female
332
41.1
73
36.7
80
39.4
74
36.3
105
52.2
Age at advanced diagnosis (years)
Mean (SD)
57.1
12.3
56.5
12.4
56.6
13.1
57.4
11.0
57.9
12.6
Range (minimum, maximum)
21
90
21
90
21
85
28
77
22
84
Ethnicitya
White/Caucasian
562
92.7
178
89.5
201
99.0
183
89.7
—
—
African/Black
14
2.3
10
5.0
0
0
4
2.0
—
—
Asian or Pacific Islander
14
2.3
6
3.0
0
0
8
3.9
—
—
Middle eastern
8
1.3
2
1.0
2
1.0
4
2.0
—
—
Indian subcontinent
8
1.3
3
1.5
0
0
5
2.5
—
—
Histologic category
Leiomyosarcoma
229
28.4
61
30.7
45
22.2
66
32.4
57
28.4
Others/NOS
183
22.7
40
20.1
35
17.2
43
21.1
65
32.3
Fibroblastic/myofibroblastic sarcoma
78
9.7
24
12.1
18
8.9
20
9.8
16
8.0
Liposarcoma
105
13.0
14
7.0
44
21.7
22
10.8
25
12.4
Vascular sarcoma
79
9.8
16
8.0
25
12.3
17
8.3
21
10.4
Rhabdomyosarcoma
86
10.7
33
16.6
20
9.9
21
10.3
12
6.0
Synovial sarcoma
47
5.8
11
5.5
16
7.9
15
7.4
5
2.5
Stage of the disease at initial diagnosis
1A
1
0.1
0
0
0
0
0
0
1
0.5
1B
20
2.5
6
3.0
5
2.5
6
2.9
3
1.5
IIA
37
4.6
7
3.5
9
4.4
3
1.5
18
9.0
IIB
87
10.8
12
6.0
30
14.8
13
6.4
32
15.9
III (with no regional lymph node metastasis)
44
5.5
6
3.0
10
4.9
9
4.4
19
9.5
III (with regional lymph node metastasis)
61
7.6
11
5.5
10
4.9
16
7.8
24
11.9
IV
557
69.0
157
78.9
139
68.5
157
77.0
104
51.7
Number of patients where initial diagnosis was not an advanced stageb
188
23.3
25
12.6
54
26.6
27
13.2
82
40.8
CCI score at advanced diagnosisc
Mean (SD)
1.0
1.1
1.0
1.1
1.0
1.0
1.0
1.1
0.8
1.2
Range (minimum, maximum)
0
6
0
5
0
4
0
6
0
6
Most common CCI conditions at advanced diagnosisc
Depression
104
12.9
23
11.6
33
16.3
29
14.2
19
9.5
Diabetes without complications
102
12.6
20
10.1
40
19.7
30
14.7
12
6.0
Hypertension
259
32.1
64
32.2
63
31.0
74
36.3
58
28.9
Anatomic location of primary tumor
Axilla
12
1.5
5
2.5
2
1.0
3
1.5
2
1.0
Breast
20
2.5
3
1.5
7
3.5
4
2.0
6
3.0
Lower extremity
187
23.2
42
21.1
53
26.1
53
26.0
39
19.4
Upper extremity
97
12.0
27
13.6
28
13.8
28
13.7
14
7.0
Head or neck
48
6.0
15
7.5
12
5.9
14
6.9
7
3.5
Gastrointestinal
38
4.7
16
8.0
5
2.5
12
5.9
5
2.5
Genitourinary
13
1.6
4
2.0
3
1.5
2
1.0
4
2.0
Gynecologic (other than uterus)
9
1.1
1
0.5
2
1.0
3
1.5
3
1.5
Mediastinum, lung, or pleura
26
3.2
4
2.0
9
4.4
7
3.4
6
3.0
Pelvis (nonvisceral)
65
8.1
23
11.6
13
6.4
17
8.3
12
6.0
Retroperitoneal
124
15.4
24
12.1
33
16.3
27
13.2
40
19.9
Trunk
67
8.3
16
8.0
11
5.4
18
8.8
22
11.0
Uterus
85
10.5
13
6.5
22
10.8
16
7.8
34
16.9
Unknown
13
1.6
6
3.0
1
0.5
0
0
6
3.0
Site of metastasis among patients with distant metastasis
Bone
105
15.9
26
14.4
30
18.1
28
15.6
21
15.6
Brain
16
2.4
3
1.7
8
4.8
2
1.1
3
2.2
Distant lymph nodes
161
24.4
56
31.1
36
21.7
51
28.3
18
13.3
Exoskeletal
28
4.2
10
5.6
6
3.6
9
5.0
3
2.2
Liver
187
28.3
58
32.2
42
25.3
56
31.1
31
23.0
Lung
468
70.8
112
62.2
125
75.3
125
69.4
106
78.5
Mediastinum
38
5.8
11
6.1
11
6.6
8
4.4
8
5.9
Pericardium
9
1.4
2
1.1
3
1.8
3
1.7
1
0.7
Peritoneum
98
14.8
32
17.8
15
9.0
30
16.7
21
15.6
Pleura
42
6.4
8
4.4
12
7.2
9
5.0
13
9.6
Retroperitoneum
18
2.7
5
2.8
5
3.0
5
2.8
3
2.2
Others
5
0.8
1
0.6
0
0
0
0
4
3.0
Unknown
2
0.3
1
0.6
1
0.6
0
0
0
0
ECOG PS at advanced diagnosis
PS 0
84
10.4
15
7.5
23
11.3
18
8.8
28
13.9
PS 1
474
58.7
162
81.4
86
42.4
144
70.6
82
40.8
PS ≥ 2
249
30.9
22
11.1
94
46.3
42
20.6
91
45.3
CCI: Charlson Comorbidity Index; ECOG: Eastern Cooperative Oncology Group; NOS: not otherwise specified; PS: performance status; SD: standard deviation; STS: soft tissue sarcoma; UK: United Kingdom; anot collected in France; bpatients with stage I, II, or III at initial diagnosis and with time from initial to advanced diagnosis greater than zero; cbecause the objective of the CCI score was to evaluate underlying comorbidity burden independent of STS, cancer was excluded from the CCI calculation for this study.
